CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million

Stock News03-31

CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.

According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134093030?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 01:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134093030","market":"nz","top_or_hot":-1,"title":"CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million","media":"Stock News","content":"<p>CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.</p>\n<p>According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-31 01:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.</p>\n<p>According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02592","symbol_name":"拨康视云-B","start_time":0,"source_url":"","article_id":"1134093030","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134093030","pubTimestamp":1774892659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02592":"拨康视云-B","BK1161":"生物科技"},"translate_title":"CLOUDBREAK-B报告年度亏损收窄6766万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02592":1},"content_text":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.\nAccording to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134093030","isCrawlerRequest":true}